cyclophosphamide | Cancer Search

Details 279 Trials 12 Therapies

A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.

codes

FDA: 8N3DW7272P

NCIt: C405

synonyms

Clafen

Neosar

Enduxan

Genoxal

Cytoxan

Endoxan

Cicloxal

Endoxana

Ledoxina

Sendoxan

Procytox

Carloxan

Cyclostin

CYCLO-cell

Fosfaseron

Cyclostine

Cytophosphan

Cycloblastin

Cycloblastine

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

129 sites for NCT04923893

Multiple Myeloma

bortezomib, +5 more drugs

cellular therapy, +4 more types

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

248 sites for NCT04109066

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

anthracycline, +4 more drugs

chemotherapy, +2 more types

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

174 sites for NCT03914625

B-Cell Lymphoblastic Leukemia/Lymphoma

asparaginase Erwinia chrysanthemi, +12 more drugs

chemotherapy, +2 more types

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

384 sites for NCT03498716

ER Negative, +2 more biomarkers

Breast Carcinoma

atezolizumab, +4 more drugs

chemotherapy, +1 more type

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

208 sites for NCT03725059

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

cyclophosphamide, +6 more drugs

chemotherapy, +3 more types

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

281 sites for NCT04824092

ALK Fusion, +4 more biomarkers

ALK-Positive Large B-Cell Lymphoma, +7 more conditions

cyclophosphamide, +6 more drugs

chemotherapy, +3 more types

Show 279 Trials for cyclophosphamide